BioSpace News Archive

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced results from a study evaluating an intramuscular (IM) method of administration for Trogarzo® (ibalizumab-uiyk), a monoclonal antibody antiretroviral therapy (ART) for the treatment of heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection failing their current antiretroviral regimen.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its initial negative opinion on the Marketing Authorisation Application (MAA) for AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name ALBRIOZA®.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX) today announced that clinical data from the dose escalation and expansion study of FHD-286 in metastatic uveal melanoma (mUM) will be presented at the ESMO Congress 2023, to be held October 20–24 in Madrid, Spain.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA.

RaySearch Laboratories AB announces that the Mass General Cancer Center plans to expand its use of RayStation®* to proton treatment planning.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for the treatment of adults and adolescents with scalp and body psoriasis.

Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a global multicenter Phase 2a study of IMG-007 in adult patients with AA.

Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay will conduct a series of meetings at the BIO Investor Forum, San Francisco on October 17-18, 2023.

Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, is proud to announce the first U.S. installation of a Trinias SCORE Opera C12 (ceiling-mounted cutting edge angiography system) at Beaufort Memorial Hospital (Beaufort, SC).

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced topline results from the INTUNE study in patients with idiopathic hypersomnia.